de GreyAD. The essential role of philanthropy in the increasingly investable rejuvenation sector. Rejuvenation Res,, 2019; 22, DOI: 10.1089/rej.2019.2198
2.
KealeyT. The Economic Laws of Scientific Research. Basingstoke, Hamps, UK: MacMillan Press Ltd, 1996.
3.
LinjakumpuT, HartikainenS, KlaukkaT, VeijolaJ, KiveläS-L, IsoahoR. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol, 2002; 55:809–817.
4.
KimH-A, ShinJ-Y, KimM-H, ParkB-J. Prevalence and predictors of polypharmacy among Korean elderly. PLoS One, 2014; 9:e98043.
5.
BanerjeeA, MbamaluD, EbrahimiS, KhanAA, ChanTF. The prevalence of polypharmacy in elderly attenders to an emergency department—A problem with a need for an effective solution. Int J Emerg Med, 2011; 4:22.
6.
SlabaughSL, MaioV, TemplinM, AbouzaidS. Prevalence and Risk of polypharmacy among the elderly in an outpatient setting. Drugs Aging, 2010; 27:1019–1028.
7.
BainsW. Venture Capital and the European Biotechnology Industry. Basingstoke, UK: Springer, 2008.
8.
DixitR, BoelsterliUA. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Disc Today, 2007; 12: 336–342.
9.
BendeleA, MccombJ, GouldT, et al.Animal models of arthritis: Relevance to human disease. Toxicol Pathol, 1999; 27:134–142.
10.
KrauseBR, PrincenHMG. Lack of predictability of classical animal models for hypolipidemic activity: A good time for mice?. Atherosclerosis, 1998; 140:15–24.
RiceJ. Animal models: Not close enough. Nature, 2012; 484:S9.
13.
MacleodM. Why animal research needs to improve. Nature, 2011; 477:511.
14.
DenayerT, StöhrT, Van RoyM. Animal models in translational medicine: Validation and prediction. New Horiz Transl Med, 2014; 2:5–11.
15.
GadSC. Animal Models in Toxicology. Abingdon, Oxford, UK: Taylor and Francis, 2006.
16.
BakerM. Inside the minds of mice and men. Nature, 2011; 475:123.
17.
TuvesonD, HanahanD. Cancer lessons from mice to humans. Nature, 2011; 471:316.
18.
AgyemanA, Ofori-AsensoR. A decade after the TGN1412 disaster: What have we learnt about safety-predicting methods for new biological agents. Pharm Pharmacol Int J, 2016; 4:00103.
19.
HorrobinDF. Modern biomedical research: An internally self-consistent universe with little contact with medical reality?. Nat Rev Drug Disc, 2003; 2:151.
20.
ScannellJW, BosleyJ. When quality beats quantity: Decision theory, drug discovery, and the reproducibility crisis. PLoS One, 2016; 11:e0147215.
21.
ScannellJW, BlanckleyA, BoldonH, WarringtonB. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Disc, 2012; 11:191.
22.
RobertsSF, FischhoffMA, SakowskiSA, FeldmanEL. Perspective: Transforming science into medicine how clinician–scientists can build bridges across research's “valley of death.” Acad Med. 2012; 87:266–270.
23.
MoranN. Public sector seeks to bridge ‘valley of death’. Nat Biotechnol, 2007; 25:266.
24.
ParthasarathyH, FishburneL. Philanthropy's role in translating scientific innovation. Nat Biotechnol, 2015; 33:1022.
25.
DanielsC. The Man Who Changed Medicine, in Fortune. New York NY, USA: Fortune Media IP Limited, 2004. http://archive.fortune.com/magazines/fortune/fortune_archive/2004/11/29/8192713/index.htm (accessed May29, 2019).
26.
OrlowskiRZ, StinchcombeTE, MitchellBS, et al.Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol, 2002; 20:4420–4427.
27.
Sánchez-SerranoI. Success in translational research: Lessons from the development of bortezomib. Nat Rev Drug Disc, 2006; 5:107–114.
RiordanJR. The cystic fibrosis transmembrane conductance regulator. Annu Rev Physiol, 1993; 55:609–630.
30.
KaiserJ. New cystic fibrosis drug offers hope, at a price. Science, 2012; 335:645.
31.
BartekRJ. Foundation-industry relationships-a new business model joint-venture philanthropy in therapy development. Curr Top Med Chem, 2014; 14:313–318.
32.
JarvisLM. Advancing R&D by venture philanthropy. Chem Eng News, 2012; 90:14–18.
33.
MorganS, GrootendorstP, LexchinJ, CunninghamC, GreysonD. The cost of drug development: A systematic review. Health Policy, 2011; 100:4–17.
34.
SertkayaA, BirkenbachA, BerlindA, EyraudJ. Examination of Clinical Trial Costs and Barriers for Drug Development. Washington, DC, USA: U.S. Department of Health and Human Services, 2014.
35.
BainsW. Truly personalised medicine: Self-experimentation in medical discovery. Med Hypotheses, 2008; 70:714–718.
36.
BainsW. The biomedical mutual organization: A new approach to developing new medical treatments. Med Hypotheses, 2008; 70:719–723.
37.
RobertsS. Self-experimentation as a source of new ideas: Ten examples about sleep, mood, health, and weight. Behav Brain Sci, 2004; 27:227–262.
38.
HanleyBP, BainsW, ChurchG. Review of scientific self-experimentation: Ethics history, regulation, scenarios, and views among ethics committees and prominent scientists. Rejuvenation Res, 2018; 22:31–42.
39.
FogartyJ, KarkarR, ZiaJ, et al.A framework for self-experimentation in personalized health. J Am Med Inform Assoc, 2015; 23:440–448.
40.
ParryGJ, BuenzEJ. Adventures in self experimentation. BMJ, 2018; 363:k5006.
41.
WicksP, VaughanTE, MassagliMP, HeywoodJ. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nat Biotechnol, 2011; 29:411.
